Here's Why Cassava Sciences Is Up 1,152% in the First Half of 2021

Shares of Cassava Sciences (NASDAQ: SAVA) skyrocketed in the first half of 2021. The biotech's share price ran up 1,152% from the first of January to the end of June.

Like most small biotech stocks that have explosive gains, the move was due to good news from a clinical trial. On Feb. 2, the company issued a press release. The headline pretty much says it all: Cassava Sciences' Simufilam Improves Cognition and Behavior in Alzheimer's Disease in Interior Analysis of Open-label Study.

image source: Getty Images.

Continue reading

Source Fool.com